Adverse events associated with teriparatide:a real-world disproportionality analysis of the Fda adverse event reporting system (faers)

Teriparatide iswidely used for osteoporosis treatment in various patients, but its safetyprofile is not fully documented. This study analyzes the FDA pharmacovigilancedatabase to assess teriparatide’s safety. Data from thefirst quarter (Q1) of 2004 to the third quarter (Q3) of 2023 were extracted andanalyzed for disproportionality between teriparatide and adverse effects (AE). A total of66,991 AE reports identified teriparatide as the principal suspect medication,aggregating to 222,116 individual AEs. Notably, healthcare professionalsauthored 16.1% of these reports (<i>n</i> = 10,809), whereas consumers accounted for themajority with 81.3% (<i>n</i> = 54,474). Teriparatide revealed a marked association withan increased propensity for musculoskeletal and connective tissue disorders (ROR,3.95; 95% CI, 3.91–3.99) at the System Organ Class (SOC) level. Concurrently,199 preferred terms (PTs) displayed significant disproportionality across allfour employed algorithms. Our studyconfirms several well-known adverse drug reactions and identifies potentialsafety issues associated with teriparatide treatment. This contributes to adeeper understanding of the complex relationship between adverse reactions andteriparatide. These findings emphasize the importance of continuous monitoringand ongoing surveillance to promptly identify and effectively manage adversereactions, thereby enhancing overall patient safety and well-being.